|
|
|
xii | |
| Dedication |
|
xiv | |
| Acknowledgements |
|
xv | |
| Introduction |
|
1 | (4) |
|
|
|
1 | (1) |
|
So why do more mothers not breastfeed? |
|
|
2 | (1) |
|
|
|
2 | (1) |
|
The safety of drugs in breastmilk |
|
|
3 | (1) |
|
Evidence for breastfeeding and the management of common conditions |
|
|
3 | (1) |
|
Counselling breastfeeding mothers |
|
|
4 | (1) |
|
PART I Breastfeeding in the wider context |
|
|
5 | (106) |
|
1 Breastfeeding in context |
|
|
6 | (9) |
|
The impact of society on breastfeeding |
|
|
6 | (3) |
|
Health inequalities and the promotion of breastfeeding |
|
|
9 | (1) |
|
Obesity and infant feeding |
|
|
9 | (1) |
|
|
|
9 | (1) |
|
Influences on breastfeeding initiation |
|
|
10 | (1) |
|
Influence of friends and family |
|
|
10 | (1) |
|
Impact of education on breastfeeding initiation |
|
|
11 | (1) |
|
Peer support in populations where breastfeeding rates are historically low |
|
|
11 | (1) |
|
Difficulties experienced with breastfeeding |
|
|
12 | (1) |
|
Exclusive breastfeeding rates |
|
|
13 | (2) |
|
2 How does breastfeeding work? |
|
|
15 | (11) |
|
Anatomy of the lactating breast |
|
|
15 | (1) |
|
|
|
16 | (1) |
|
|
|
17 | (1) |
|
|
|
17 | (1) |
|
|
|
18 | (2) |
|
Inhibition of milk production |
|
|
20 | (1) |
|
|
|
21 | (1) |
|
How can healthcare professionals support breastfeeding mothers? |
|
|
22 | (1) |
|
Assessing attachment and drainage of the breast |
|
|
23 | (1) |
|
Assessment of infant stools as an indicator of good milk transfer |
|
|
23 | (1) |
|
|
|
24 | (1) |
|
|
|
25 | (1) |
|
3 Constituents of breastmilk and formula milk |
|
|
26 | (6) |
|
Breastmilk --- a remarkable liquid |
|
|
26 | (1) |
|
|
|
27 | (1) |
|
|
|
28 | (1) |
|
|
|
29 | (1) |
|
|
|
29 | (1) |
|
Secretory immunoglobulin A |
|
|
30 | (1) |
|
Anti-inflammatory molecules |
|
|
30 | (1) |
|
|
|
30 | (1) |
|
|
|
30 | (1) |
|
|
|
30 | (1) |
|
So how do these factors protect the breastfed infant? |
|
|
30 | (1) |
|
|
|
31 | (1) |
|
4 Understanding the importance of breastmilk |
|
|
32 | (7) |
|
The positive health benefits of breastfeeding |
|
|
32 | (3) |
|
Implications for the healthcare system |
|
|
35 | (1) |
|
Maternal beliefs about breastfeeding and its advantages |
|
|
36 | (1) |
|
Disadvantages of breastfeeding |
|
|
36 | (1) |
|
Medical disadvantages of breastfeeding |
|
|
37 | (1) |
|
|
|
37 | (1) |
|
Maple syrup urine disease |
|
|
38 | (1) |
|
|
|
38 | (1) |
|
5 Treating conditions related to breastfeeding |
|
|
39 | (22) |
|
Conditions affecting the breastfeeding mother |
|
|
40 | (1) |
|
|
|
40 | (1) |
|
|
|
40 | (3) |
|
|
|
43 | (1) |
|
|
|
43 | (1) |
|
|
|
43 | (2) |
|
|
|
45 | (1) |
|
Conditions affecting the baby |
|
|
46 | (1) |
|
|
|
46 | (1) |
|
Cow's milk protein allergy |
|
|
47 | (1) |
|
|
|
48 | (1) |
|
|
|
49 | (1) |
|
|
|
50 | (1) |
|
|
|
51 | (1) |
|
Conditions that may affect the mother and baby during breastfeeding |
|
|
52 | (1) |
|
|
|
52 | (2) |
|
Medication for women who may become pregnant |
|
|
54 | (1) |
|
Pre-conceptual use of medication |
|
|
54 | (1) |
|
|
|
54 | (1) |
|
|
|
55 | (1) |
|
|
|
55 | (2) |
|
|
|
57 | (1) |
|
|
|
57 | (1) |
|
Vaping (electronic cigarettes) |
|
|
58 | (1) |
|
|
|
59 | (1) |
|
|
|
59 | (1) |
|
|
|
60 | (1) |
|
6 Decision-making on the safety of drugs in breastmilk |
|
|
61 | (13) |
|
The dilemma of prescribing |
|
|
62 | (1) |
|
Assessment of the transfer of drugs in breastmilk |
|
|
62 | (1) |
|
Pharmacokinetic data on the transfer of drugs into breastmilk |
|
|
63 | (2) |
|
Factors influencing drug transfer into breastmilk |
|
|
65 | (1) |
|
The extent of plasma protein binding of the drug |
|
|
65 | (1) |
|
|
|
65 | (1) |
|
|
|
65 | (1) |
|
|
|
65 | (1) |
|
|
|
66 | (1) |
|
The size of the drug molecule |
|
|
66 | (1) |
|
|
|
66 | (1) |
|
|
|
67 | (1) |
|
|
|
68 | (1) |
|
Immaturity of the hepatic and renal function of infants |
|
|
68 | (1) |
|
|
|
68 | (1) |
|
|
|
68 | (1) |
|
|
|
69 | (1) |
|
Age of the baby and volume of milk consumed |
|
|
69 | (1) |
|
Possible side effects for the baby |
|
|
69 | (1) |
|
|
|
69 | (1) |
|
Duration of exposure to the drug |
|
|
70 | (1) |
|
|
|
70 | (1) |
|
Summary of points to determine when a drug is likely to be safe for use during breastfeeding |
|
|
70 | (1) |
|
Limitations of the literature on transfer of drugs into breastmilk |
|
|
70 | (1) |
|
Practical application of pharmacological data |
|
|
71 | (2) |
|
|
|
73 | (1) |
|
7 Professional responsibility and counselling |
|
|
74 | (18) |
|
The dilemma of taking prescription drugs during breastfeeding |
|
|
74 | (1) |
|
How do mothers perceive the dilemma of drugs during breastfeeding? |
|
|
75 | (1) |
|
|
|
76 | (4) |
|
Involving the parents in decision-making |
|
|
80 | (3) |
|
Information on the use of medication from the mother's viewpoint |
|
|
83 | (1) |
|
Professional decisions and liability |
|
|
84 | (1) |
|
Phrasing of information to parents |
|
|
85 | (1) |
|
|
|
85 | (2) |
|
How is counselling different from medical advice? |
|
|
87 | (1) |
|
|
|
87 | (4) |
|
|
|
91 | (1) |
|
8 Chronic diseases and medication in the breastfeeding mother |
|
|
92 | (19) |
|
|
|
92 | (2) |
|
|
|
94 | (1) |
|
|
|
95 | (1) |
|
Polycystic Ovary Syndrome (PCOS) |
|
|
96 | (2) |
|
Obsessional Compulsive Disorder (OCT)) |
|
|
98 | (1) |
|
|
|
98 | (1) |
|
Systemic lupus erythematosus (lupus) |
|
|
99 | (1) |
|
|
|
100 | (1) |
|
|
|
101 | (2) |
|
|
|
103 | (2) |
|
Inflammatory bowel disease (IBD) |
|
|
105 | (2) |
|
|
|
107 | (1) |
|
|
|
108 | (1) |
|
Medical management of miscarriage |
|
|
109 | (1) |
|
|
|
109 | (1) |
|
Hyperemesis/morning sickness |
|
|
109 | (1) |
|
|
|
110 | (1) |
|
PART II The safety of drugs in breastmilk |
|
|
111 | (216) |
|
9 Information on level of drugs into breastmilk |
|
|
112 | (215) |
|
Sources used to compile this information |
|
|
113 | (1) |
|
|
|
114 | (1) |
|
Medications and Mothers' Milk |
|
|
114 | (1) |
|
|
|
114 | (1) |
|
The British National Formulary (BNF) |
|
|
115 | (1) |
|
The British National Formulary for Children (BNFC) |
|
|
115 | (1) |
|
|
|
116 | (1) |
|
|
|
116 | (1) |
|
|
|
117 | (1) |
|
|
|
117 | (3) |
|
|
|
120 | (2) |
|
Proton pump inhibitors (PPIs) |
|
|
122 | (3) |
|
Anti-diarrhoea medication |
|
|
125 | (2) |
|
Inflammatory bowel disease (IBD) |
|
|
127 | (5) |
|
|
|
132 | (1) |
|
|
|
133 | (5) |
|
Haemorrhoidal preparations |
|
|
138 | (1) |
|
|
|
138 | (2) |
|
|
|
140 | (1) |
|
|
|
140 | (2) |
|
|
|
142 | (4) |
|
|
|
146 | (4) |
|
Angiotensin II receptor antagonists |
|
|
150 | (2) |
|
|
|
152 | (2) |
|
|
|
154 | (1) |
|
|
|
155 | (3) |
|
The novel (non-Vitamin K antagonist) oral anticoagulants (NOAC) |
|
|
158 | (1) |
|
|
|
159 | (2) |
|
|
|
161 | (1) |
|
|
|
162 | (1) |
|
|
|
163 | (1) |
|
Long-acting beta2 agonists |
|
|
164 | (1) |
|
|
|
165 | (2) |
|
Leukotriene receptor antagonists |
|
|
167 | (1) |
|
|
|
168 | (5) |
|
|
|
173 | (1) |
|
|
|
173 | (1) |
|
|
|
174 | (2) |
|
|
|
176 | (1) |
|
|
|
176 | (3) |
|
|
|
179 | (3) |
|
|
|
182 | (9) |
|
Drugs to treat bipolar disorder |
|
|
191 | (2) |
|
|
|
193 | (3) |
|
Selective serotonin re-uptake inhibitors (SSRIs) |
|
|
196 | (6) |
|
Serotonin and noradrenaline re-uptake inhibitors |
|
|
202 | (1) |
|
Alpha2-adrenoreceptor antagonist |
|
|
203 | (1) |
|
|
|
204 | (1) |
|
Drugs used to treat nausea and vertigo |
|
|
205 | (5) |
|
|
|
210 | (5) |
|
|
|
215 | (4) |
|
|
|
219 | (2) |
|
|
|
221 | (8) |
|
|
|
229 | (6) |
|
|
|
235 | (4) |
|
Nicotine replacement therapy |
|
|
239 | (2) |
|
|
|
241 | (1) |
|
|
|
242 | (1) |
|
|
|
242 | (18) |
|
|
|
260 | (4) |
|
|
|
264 | (2) |
|
Neuraminidase inhibitors to treat influenza (H1N1/H5N1) |
|
|
266 | (2) |
|
|
|
268 | (3) |
|
|
|
271 | (1) |
|
|
|
271 | (1) |
|
|
|
271 | (3) |
|
|
|
274 | (3) |
|
|
|
277 | (1) |
|
|
|
277 | (1) |
|
Parenteral progestogen-only contraceptives |
|
|
277 | (1) |
|
Oral progestogen-only contraceptive pills (POPs) |
|
|
278 | (1) |
|
Intrauterine progestogen-only contraceptives |
|
|
278 | (1) |
|
Combined oral contraceptive (COC) |
|
|
278 | (1) |
|
Emergency hormonal contraception (EHC) |
|
|
279 | (1) |
|
|
|
280 | (3) |
|
|
|
283 | (6) |
|
Drugs used lo induce or augment labour |
|
|
289 | (1) |
|
Medical termination of pregnancy |
|
|
290 | (2) |
|
|
|
292 | (1) |
|
|
|
293 | (1) |
|
|
|
293 | (1) |
|
|
|
293 | (5) |
|
Druids used to treat musculoskeletal and joint pains |
|
|
298 | (1) |
|
Non-steroidal anti-inflammatories |
|
|
298 | (3) |
|
Rheumatic disease-suppressing drugs |
|
|
301 | (1) |
|
|
|
302 | (1) |
|
|
|
303 | (1) |
|
|
|
304 | (1) |
|
|
|
304 | (2) |
|
|
|
306 | (1) |
|
|
|
306 | (1) |
|
|
|
307 | (1) |
|
|
|
307 | (1) |
|
|
|
307 | (1) |
|
|
|
308 | (1) |
|
|
|
308 | (1) |
|
|
|
308 | (1) |
|
|
|
309 | (1) |
|
|
|
309 | (1) |
|
Topical antibacterials, antifungals and antivirals |
|
|
309 | (1) |
|
|
|
310 | (2) |
|
|
|
312 | (8) |
|
|
|
320 | (1) |
|
|
|
320 | (4) |
|
|
|
324 | (1) |
|
|
|
324 | (1) |
|
|
|
325 | (2) |
| Conclusion |
|
327 | (3) |
| Appendix |
|
330 | (2) |
| References |
|
332 | (9) |
| Index |
|
341 | |